Protagenic Therapeutics Secures Five Million Dollars to Advance Novel Anxiety Treatment

New York, Wednesday, 11 November 2026.
Protagenic secured up to $5 million to launch its first U.S. clinical trial for generalized anxiety disorder in 2027, backed by favorable FDA review and clean international safety data.